Literature DB >> 32927523

Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression.

Raymond Pranata1, Ian Huang2, Michael Anthonius Lim3, Eka Julianta Wahjoepramono4, Julius July4.   

Abstract

BACKGROUND: We conducted a systematic review and meta-analysis to evaluate the latest evidence on the association between cerebrovascular, and cardiovascular diseases and poor outcome in patients with Coronavirus Disease 2019 (COVID-19) pneumonia.
METHODS: A comprehensive systematic literature search was performed using PubMed, SCOPUS, EuropePMC, and Cochrane Central Database. The outcome of interest was composite poor outcome that comprised of mortality and severe COVID-19.
RESULTS: A total of 4448 patients were obtained from 16 studies. Cerebrovascular disease was associated with an increased composite poor outcome (RR 2.04 [1.43,2.91], p<0.001; I2: 77%). Subgroup analysis revealed that cerebrovascular disease was associated with mortality (RR 2.38 [1.92,2.96], p<0.001; I2: 0%) and showed borderline significance for severe COVID-19 (RR 1.88 [1.00,3.51], p = 0.05; I2: 87%). Cardiovascular disease was associated with increased composite poor outcome (RR 2.23 [1.71,2.91], p<0.001; I2: 60%), mortality (RR 2.25 [1.53,3.29], p<0.001; I2: 33%) and severe COVID-19 (RR 2.25 [1.51,3.36], p<0.001; I2: 76%). Meta-regression demonstrate that the association was not influenced by gender, age, hypertension, diabetes, and respiratory comorbidities. Furthermore, the association between cerebrovascular disease and poor outcome was not affected by cardiovascular diseases and vice versa.
CONCLUSION: Cerebrovascular and cardiovascular diseases were associated with an increased risk for poor outcome in patients with COVID-19.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; Cardiovascular; Cerebrovascular; Mortality; Severity

Mesh:

Year:  2020        PMID: 32927523     DOI: 10.1016/j.jstrokecerebrovasdis.2020.104949

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  22 in total

1.  Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment.

Authors:  Yaoyun Niu; Yang Chen; Pengbo Sun; Yangyang Wang; Jingyi Luo; Yipei Ding; Weidong Xie
Journal:  Int Immunopharmacol       Date:  2021-05-09       Impact factor: 5.714

2.  Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies.

Authors:  Sebastian Bertram; Thiemo Pfab; Christian Albert; Sven Schmidt; Jürgen Passfall; Martin Haesner; Maximilian Seidel; Bodo Hölzer; Felix S Seibert; Adrian Doevelaar; Benjamin Rohn; Panagiota Zgoura; Nina Babel; Timm H Westhoff
Journal:  Ther Apher Dial       Date:  2022-03-29       Impact factor: 2.195

3.  Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes.

Authors:  Mayank Batra; Runxia Tian; Chongxu Zhang; Emile Clarence; Camila Sofia Sacher; Justin Nestor Miranda; Justin Rafa O De La Fuente; Megan Mathew; Desmond Green; Sayari Patel; Maria Virginia Perez Bastidas; Sara Haddadi; Mukunthan Murthi; Miguel Santiago Gonzalez; Shweta Kambali; Kayo H M Santos; Huda Asif; Farzaneh Modarresi; Mohammad Faghihi; Mehdi Mirsaeidi
Journal:  Sci Rep       Date:  2021-02-10       Impact factor: 4.379

Review 4.  Cardiovascular drugs and COVID-19 clinical outcomes: A living systematic review and meta-analysis.

Authors:  Innocent G Asiimwe; Sudeep Pushpakom; Richard M Turner; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2021-07-07       Impact factor: 3.716

5.  Association of Preexisting Asthma and Other Allergic Diseases With Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis.

Authors:  Xianbo Wu; Yihua Xu; Lina Jin; Xiaoou Wang; Haiyan Zhu; Yiqiang Xie
Journal:  Front Med (Lausanne)       Date:  2021-06-24

6.  Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis.

Authors:  Wenjie Tian; Wanlin Jiang; Jie Yao; Christopher J Nicholson; Rebecca H Li; Haakon H Sigurslid; Luke Wooster; Jerome I Rotter; Xiuqing Guo; Rajeev Malhotra
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693

Review 7.  Neurological manifestations of COVID-19, SARS and MERS.

Authors:  Kato Verstrepen; Laure Baisier; Harald De Cauwer
Journal:  Acta Neurol Belg       Date:  2020-07-21       Impact factor: 2.471

8.  The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection.

Authors:  E Moro; A Priori; E Beghi; R Helbok; L Campiglio; C L Bassetti; E Bianchi; L F Maia; S Ozturk; F Cavallieri; M Zedde; J Sellner; D Bereczki; M Rakusa; G Di Liberto; A Sauerbier; A Pisani; A Macerollo; R Soffietti; P Taba; M Crean; A Twardzik; C Oreja-Guevara; B Bodini; T M Jenkins; T J von Oertzen
Journal:  Eur J Neurol       Date:  2020-07-23       Impact factor: 6.288

Review 9.  Vascular Manifestations of COVID-19 - Thromboembolism and Microvascular Dysfunction.

Authors:  Kirsty A Roberts; Liam Colley; Thomas A Agbaedeng; Georgina M Ellison-Hughes; Mark D Ross
Journal:  Front Cardiovasc Med       Date:  2020-10-26

10.  Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis.

Authors:  Eman A Toraih; Rami M Elshazli; Mohammad H Hussein; Abdelaziz Elgaml; Mohamed Amin; Mohammed El-Mowafy; Mohamed El-Mesery; Assem Ellythy; Juan Duchesne; Mary T Killackey; Keith C Ferdinand; Emad Kandil; Manal S Fawzy
Journal:  J Med Virol       Date:  2020-07-06       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.